发布求助
文献互助 智能选刊 最新文献

International Journal of Hematologic Oncology最新文献

筛选
英文 中文
Primary diffuse large B-cell lymphoma of the CNS: a rare case of spontaneous remission. 中枢神经系统原发性弥漫性大b细胞淋巴瘤:一例罕见的自发缓解病例。
International Journal of Hematologic Oncology Pub Date : 2017-11-01 Epub Date: 2017-11-20 DOI: 10.2217/ijh-2017-0009
Fotini Debonera, Sunita Nasta, Maria Martinez-Lage, Stephen J Schuster, Donald E Tsai
{"title":"Primary diffuse large B-cell lymphoma of the CNS: a rare case of spontaneous remission.","authors":"Fotini Debonera,&nbsp;Sunita Nasta,&nbsp;Maria Martinez-Lage,&nbsp;Stephen J Schuster,&nbsp;Donald E Tsai","doi":"10.2217/ijh-2017-0009","DOIUrl":"https://doi.org/10.2217/ijh-2017-0009","url":null,"abstract":"<p><p>There is no consensus on the optimal therapy for primary CNS lymphoma. Conventional treatment modalities include chemotherapy and radiation therapy, which carry significant risks of morbidity and mortality. In systemic lymphomas, there are situations where non-Hodgkin lymphomas have resolved spontaneously. We now report the case of a nonimmunocompromised patient with primary CNS lymphoma who underwent a spontaneous remission with a durable response. This case suggests that not all patients with primary CNS lymphomas require aggressive treatment with chemotherapy and radiation therapy.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 3","pages":"69-73"},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36609875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
How can we better predict treatment outcomes in classical Hodgkin's lymphoma? 我们如何更好地预测经典霍奇金淋巴瘤的治疗结果?
International Journal of Hematologic Oncology Pub Date : 2017-11-01 Epub Date: 2017-11-20 DOI: 10.2217/ijh-2017-0010
Claudio Agostinelli
{"title":"How can we better predict treatment outcomes in classical Hodgkin's lymphoma?","authors":"Claudio Agostinelli","doi":"10.2217/ijh-2017-0010","DOIUrl":"https://doi.org/10.2217/ijh-2017-0010","url":null,"abstract":"“ The results indicate that response-adapted therapy based on PET-2 results guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated with ABVD. ”","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 3","pages":"65-68"},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opportunities for targeting gene regulatory factors in B-cell acute lymphoblastic leukemia. 靶向b细胞急性淋巴细胞白血病基因调控因子的机会。
International Journal of Hematologic Oncology Pub Date : 2017-11-01 Epub Date: 2017-11-20 DOI: 10.2217/ijh-2017-0018
Christopher J Ott
{"title":"Opportunities for targeting gene regulatory factors in B-cell acute lymphoblastic leukemia.","authors":"Christopher J Ott","doi":"10.2217/ijh-2017-0018","DOIUrl":"https://doi.org/10.2217/ijh-2017-0018","url":null,"abstract":"“ there is intriguing experimental evidence to suggest targeting gene regulatory factors with pharmaceutical agents could be an effective therapeutic strategy for B-ALL. ” Modern chemotherapy regimens have had a profound impact on the prognosis of individuals diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), especially children [1] . However these treatments achieve substantially poorer survival rates in adults, and are associated with significant short- and long-term toxicities. An advanced understanding of the genetic complexity that characterizes B-ALL allows for more precise patient stratification, and reveals disease subtypes that are at a high-risk for treatment relapse [2] . This genetic profiling has also revealed opportunities for the development of targeted therapies. For example, recurrent BCR–ABL1 translocations define a unique subtype of ALL found in 2–4% of pediatric and at least 25% of adult cases. The activity of this oncogene can be effectively inhibited with the tyrosine kinase inhibitor imatinib, with promising clinical results [3] . Intriguingly, many ALL oncogenes include gene fusions and translocations of transcription regulators and other chromatin associated factors (e.g., ETV6–RUNX1 , TCF3–PBX1 , MYC or MLL rearrangements), revealing the disease to be primarily one of disrupted gene expression control. The mechanistic aspects of these oncogenes are incompletely understood, yet remain an active area of research. These factors can unfortunately also often be viewed as intractable for therapeutics development. Yet much recent progress has been made in targeting gene regulatory complexes with small molecule pharmaceutical agents [4] . Additionally, promising preclinical and early clinical data in B-ALL","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 3","pages":"57-59"},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic lymphocytic leukemia: "The times they are a-changin". 慢性淋巴细胞白血病:“时代正在改变”。
International Journal of Hematologic Oncology Pub Date : 2017-06-01 Epub Date: 2017-11-17 DOI: 10.2217/ijh-2017-0007
Stefano Molica
{"title":"Chronic lymphocytic leukemia: <i>\"The times they are a-changin\"</i>.","authors":"Stefano Molica","doi":"10.2217/ijh-2017-0007","DOIUrl":"https://doi.org/10.2217/ijh-2017-0007","url":null,"abstract":"“ the advent of targeted therapy in CLL requires the urgent introduction of revised clinical guidelines based not only on results of clinical trials but also including data from clinical practice and the assessment of drug-related toxicity according patients’ reported outcomes ”","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 2","pages":"27-29"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated classification and novel treatment prospective for nodal peripheral T-cell lymphomas. 淋巴结周围t细胞淋巴瘤的最新分类和新的治疗前景。
International Journal of Hematologic Oncology Pub Date : 2017-06-01 Epub Date: 2017-06-30 DOI: 10.2217/ijh-2017-0006
Pier Paolo Piccaluga
{"title":"Updated classification and novel treatment prospective for nodal peripheral T-cell lymphomas.","authors":"Pier Paolo Piccaluga","doi":"10.2217/ijh-2017-0006","DOIUrl":"https://doi.org/10.2217/ijh-2017-0006","url":null,"abstract":"","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current challenges in the management of follicular lymphoma. 当前滤泡性淋巴瘤治疗面临的挑战。
International Journal of Hematologic Oncology Pub Date : 2017-06-01 Epub Date: 2017-06-30 DOI: 10.2217/ijh-2017-0003
Maryam Sarraf Yazdy, Chaitra Ujjani
{"title":"Current challenges in the management of follicular lymphoma.","authors":"Maryam Sarraf Yazdy, Chaitra Ujjani","doi":"10.2217/ijh-2017-0003","DOIUrl":"10.2217/ijh-2017-0003","url":null,"abstract":"<p><p>Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevitably relapse. The inability to achieve a complete remission and an early progression of disease have recently been determined to be indicative of poorer long-term outcomes. A greater understanding of the pathogenesis of follicular lymphoma has enabled the development of targeted therapies, which may improve standard treatment approaches. Examples include lenalidomide and obinutuzumab, which are currently in front-line Phase III investigation. Other therapies of interest include small molecule inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 1","pages":"13-24"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171972/pdf/ijh-06-13.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survivors at risk: Hodgkin lymphoma survivors at high risk of second cancers. 高危幸存者:第二癌症高风险的霍奇金淋巴瘤幸存者。
International Journal of Hematologic Oncology Pub Date : 2017-06-01 Epub Date: 2017-06-30 DOI: 10.2217/ijh-2017-0008
Amit Sud
{"title":"Survivors at risk: Hodgkin lymphoma survivors at high risk of second cancers.","authors":"Amit Sud","doi":"10.2217/ijh-2017-0008","DOIUrl":"https://doi.org/10.2217/ijh-2017-0008","url":null,"abstract":"<p><p><b>Amit Sud speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Amit Sud is a clinical research fellow in Hematology at the Institute of Cancer Research, UK. He undertook his undergraduate medical training at the University of Manchester, gaining an honors degree. He completed his Masters in Medical Research at Manchester University, gaining a distinction. He continued his medical training in Manchester and London and started his specialization in Hematology in South West London. He was successful in obtaining a Cancer Research UK funded clinical research fellowship in Hematology under the supervision of Professor Richard Houlston at the Institute of Cancer Research. His current research focus is that of genetic susceptibility to Hodgkin lymphoma. He is a trainee member of the NCRI Lymphoma Clinical Studies Group.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 1","pages":"5-8"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36205089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The bone marrow transplant clinical nurse specialist in hemato-oncology: an interview with Anthony Nolan Nurse Specialist Susan Paskar. 血液肿瘤学骨髓移植临床护士专家:采访安东尼·诺兰护士专家苏珊·帕斯卡。
International Journal of Hematologic Oncology Pub Date : 2017-06-01 Epub Date: 2017-06-30 DOI: 10.2217/ijh-2017-0014
Susan Paskar
{"title":"The bone marrow transplant clinical nurse specialist in hemato-oncology: an interview with Anthony Nolan Nurse Specialist Susan Paskar.","authors":"Susan Paskar","doi":"10.2217/ijh-2017-0014","DOIUrl":"https://doi.org/10.2217/ijh-2017-0014","url":null,"abstract":"<p><p><b>Susan Paskar speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Susan qualified in 1997 as a registered nurse and has 20 years of experience, in a range of specialties including hematology, medical and surgical oncology, general surgery, bariatric, breast, endocrine, head & neck, liver, urology and bone marrow/stem cell transplant. Working in both the UK and the USA, in regional transplant centers since 2002, she is considered expert in care of the bone marrow transplant patient from point of referral to long term follow-up care and palliation. She has been responsible for development and implementation of a Nurse-led late-effects post-bone marrow transplant service at the Freeman Hospital in Newcastle upon Tyne, as their Anthony Nolan Nurse Specialist.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 1","pages":"9-11"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting sphingosine kinase 1 in acute myeloid leukemia: translation to clinic. 针对鞘氨醇激酶1治疗急性髓系白血病的临床研究。
International Journal of Hematologic Oncology Pub Date : 2017-06-01 Epub Date: 2017-07-18 DOI: 10.2217/ijh-2017-0011
Jason A Powell, Craig T Wallington-Beddoe, Stuart M Pitson
{"title":"Targeting sphingosine kinase 1 in acute myeloid leukemia: translation to clinic.","authors":"Jason A Powell,&nbsp;Craig T Wallington-Beddoe,&nbsp;Stuart M Pitson","doi":"10.2217/ijh-2017-0011","DOIUrl":"https://doi.org/10.2217/ijh-2017-0011","url":null,"abstract":"Acute myeloid leukemia (AML) is an aggressive heterogeneous group of malignancies resulting from various oncogenic genetic lesions that presents as an accumulation of immature myeloid cells in the bone marrow and peripheral blood. Standard induction chemotherapeutics have remained the front line therapy for AML for over 30 years, and despite being often highly effective at achieving initial disease remission, these responses are often short-lived resulting in relapse and death. Indeed, the overall survival in young adults ( < 60 years) is < 30% [1] . Unlike the ever-increasing repertoire of targeted therapies for lymphoproliferative disorders, currently all- trans-retinoic-acid represents the only targeted therapy in routine clinical use for the treatment of one subclass of AML, acute promyelocytic leukemia, with this approach yielding a more favorable prognosis in this AML subtype than presently achievable in any other form of AML. No targeted therapies are in routine clinical use for the remaining subtypes of AML, which constitute about 90% of all AML patients, and thus, there is an enormous unmet need to develop such targeted therapies.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 2","pages":"31-34"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Understanding the molecular basis of acute myeloid leukemias: where are we now? 了解急性髓性白血病的分子基础:我们现在在哪里?
International Journal of Hematologic Oncology Pub Date : 2017-06-01 Epub Date: 2017-11-17 DOI: 10.2217/ijh-2017-0002
Alicja M Gruszka, Debora Valli, Myriam Alcalay
{"title":"Understanding the molecular basis of acute myeloid leukemias: where are we now?","authors":"Alicja M Gruszka,&nbsp;Debora Valli,&nbsp;Myriam Alcalay","doi":"10.2217/ijh-2017-0002","DOIUrl":"https://doi.org/10.2217/ijh-2017-0002","url":null,"abstract":"<p><p>Although the treatment modalities for acute myeloid leukemia (AML) have not changed much over the past 40 years, distinct progress has been made in deciphering the basic biology underlying the pathogenesis of this group of hematological disorders. Studies show that AML development is a multicause, multistep and multipathway process. Accordingly, AMLs constitute a heterogeneous group of diseases. The thorough understanding of the molecular basis of AML is paving the way for better therapeutic approaches. Multiple novel drugs are being introduced and new, more efficient and less toxic formulations of conventional therapeutics are becoming available. Here, we review the recent advances in the comprehension of the molecular processes that lead to the onset of AML and its translation into clinical practice.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"6 2","pages":"43-53"},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信